The Indian company Biocon has stated that prelimary data from late-stage clinical trials on its experimental oral insulin drug for diabetes has not achieved the results anicipated.
However, the company stated that it is still committed to developing the drug for worldwide consumption.
In the final-stage trials which were undertaken in India, IN-105 did not achieve its primary target of reducing HbA1c levels, or a haemoglobin count, in type 2 diabetics .
India's leading biotech company confirmed that diabetics were poorly controlled on the drug in contrast to those on a placebo.
However, the company added that the drug had achieved secondary targets on safety and efficacy .
The company is intending to to commence its search for a global pharmaceutical partner to further develop the drug for those with type 2 diabetes .
Oral Insulin Does Not Achieve Primary Target for Diabetics
Tue, 11 Jan 2011
Recommended links
Diabetic Life Insurance Quote for a Single PersonDiabetic Life Insurance Quote for One Diabetic and One Non Diabetic
Diabetic Life Insurance Quote where Both Partners are Diabetic
Diabetes Related Books
The Importance of Life Insurance
Diabetes Portal
Diabetics Missing Out on their Insulin
Novo States Cancer Risk with Insulin Decreases Over Time
Sanofi Aventis Removes Insulin Pens from Market
Breakthrough Protects Diabetics from Insulin Side Effects
New Pill Could Banish Daily Insulin Jabs for Diabetics
New Type of Insulin Pump Being Developed